ES8202584A1 - Un procedimiento para la preparacion de una vacuna viral vi-va estabilizada y mejorada. - Google Patents

Un procedimiento para la preparacion de una vacuna viral vi-va estabilizada y mejorada.

Info

Publication number
ES8202584A1
ES8202584A1 ES496358A ES496358A ES8202584A1 ES 8202584 A1 ES8202584 A1 ES 8202584A1 ES 496358 A ES496358 A ES 496358A ES 496358 A ES496358 A ES 496358A ES 8202584 A1 ES8202584 A1 ES 8202584A1
Authority
ES
Spain
Prior art keywords
stabilizer
liquid
vaccine containing
vaccines
disaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES496358A
Other languages
English (en)
Other versions
ES496358A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of ES496358A0 publication Critical patent/ES496358A0/es
Publication of ES8202584A1 publication Critical patent/ES8202584A1/es
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18411Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSICION DE UN ESTABILIZANTE PARA VACUNAS VIRALES LIQUIDAS. CONSTA, EN PARTES EN PESO, DE 1,5 A 2,1 PARTES DE GELATINA PARCIALMENTE HIDROLIZADA, DE 7 A 13 PARTES DE UN MONOSACARIDO O DISACARIDO, SACAROSA, LACTOSA O MALTOSA, DE 0,4 A 0,6 PARTES DE UN MEDIO DE CULTIVO DE CEDULAS IN VITRO, DE 0,35 A 0,7 PARTES DE ACIDO L-GLUMATICO, DE 0,75 A 1,3 PARTES DE L-ARGININA Y UNA CANTIDAD DE TAMPON ACIDO, PRINCIPALMENTE TAMPON DE FOSFATO, FISIOLOGICAMENTE ACEPTABLE, ADECUADA PARA MANTENER EL PH ENTRE 6 Y 6,5 APROXIMADAMENTE. ES APLICABLE A VACUNAS VIRALES LIQUIDAS COMO SARAMPION, PAPERAS, RUBEOLA, SINFITIAL RESPIRATORIA Y CITOMEGALOVIRUS.
ES496358A 1979-10-29 1980-10-28 Un procedimiento para la preparacion de una vacuna viral vi-va estabilizada y mejorada. Expired ES8202584A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8906879A 1979-10-29 1979-10-29
US11870380A 1980-02-05 1980-02-05

Publications (2)

Publication Number Publication Date
ES496358A0 ES496358A0 (es) 1982-02-01
ES8202584A1 true ES8202584A1 (es) 1982-02-01

Family

ID=26780218

Family Applications (1)

Application Number Title Priority Date Filing Date
ES496358A Expired ES8202584A1 (es) 1979-10-29 1980-10-28 Un procedimiento para la preparacion de una vacuna viral vi-va estabilizada y mejorada.

Country Status (7)

Country Link
EP (1) EP0028563B1 (es)
DE (1) DE3067376D1 (es)
DK (1) DK159100C (es)
ES (1) ES8202584A1 (es)
GR (1) GR70319B (es)
IE (1) IE50276B1 (es)
PT (1) PT71926B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5716823A (en) * 1980-07-03 1982-01-28 Green Cross Corp:The Live mumps vaccine pharmaceutical and stabilizing method
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
CA1206094A (en) * 1981-01-09 1986-06-17 Thomas P. Hopp Synthetic antigenic composition and process for making same
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
FR2532548B1 (fr) * 1982-09-03 1985-11-08 Pasteur Institut Nouveau procede de production de vaccins presentant un titre eleve de virus et vaccins tres purifies, a titre eleve de virus, ainsi obtenus
ZA874625B (en) * 1986-06-30 1988-10-26 Smith Kline Rit Stabilizers for live vaccines,process for their preparation and vaccines containing them
JPS63307827A (ja) * 1987-06-08 1988-12-15 Kitasato Inst:The 安定化された生ウイルスワクチンおよびその製造法
WO1992020375A1 (en) * 1991-05-17 1992-11-26 Merck & Co., Inc. Non-stinging measles-mumps-rubella vaccine composition
AU2088992A (en) * 1992-05-05 1993-11-11 Research Foundation For Microbial Diseases Of Osaka University, The Stabilized live vaccine
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
WO1998028000A1 (en) * 1996-12-20 1998-07-02 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6051238A (en) * 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
WO2002009749A2 (en) * 2000-07-31 2002-02-07 Aventis Pasteur Limited Respiratory syncytial virus vaccine
WO2006052813A2 (en) * 2004-11-05 2006-05-18 Wellstat Biologics Corporation Stable and filterable enveloped virus formulations
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
EP1973406B1 (en) 2005-12-28 2014-03-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form
CA2673120C (en) 2006-12-18 2012-08-07 Advanced Bionutrition Corporation A dry food product containing live probiotic
US9623094B2 (en) 2009-03-27 2017-04-18 Advanced Bionutrition Corporation Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
KR101799983B1 (ko) 2009-05-26 2017-12-20 어드밴스드 바이오뉴트리션 코프. 생물학적 활성 미생물 및/또는 생활성 물질을 포함하는 안정한 건식분말 조성물 및 제조 방법
WO2011094469A2 (en) 2010-01-28 2011-08-04 Advanced Bionutrition Corporation Dry glassy composition comprising a bioactive material
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
CL2011001984A1 (es) 2010-08-13 2012-06-29 Advanced Bionutrition Corp Composicion seca estabilizadora para material biologico que comprende carbohidrato, proteinas hidrolizadas de animal o de planta y un componente de acido carboxilico; metodo de preparacion; y formulacion de entrega oral que comprende la composicion seca estabilizadora.
ES2765880T3 (es) 2012-01-09 2020-06-11 Sanofi Pasteur Biologics Llc Purificación del virus del herpes
CA2873775C (en) 2012-05-21 2021-04-20 Sanofi Pasteur Limited Herpesvirus compositions and related methods
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
US12558395B2 (en) 2015-07-29 2026-02-24 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
BR112018001784B1 (pt) 2015-07-29 2022-05-10 Advanced Bionutrition Corp Composições probióticas secas estáveis para usos dietéticos especiais, seu método de preparação e método de preparação de uma fórmula para bebês
EP3980058A1 (en) * 2019-06-10 2022-04-13 Boehringer Ingelheim Animal Health USA Inc. Stabilized liquid live vaccine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE665076A (es) * 1963-12-23 1965-12-08
BE641705A (es) * 1963-12-23 1964-06-23
FR2076787A5 (en) * 1970-01-28 1971-10-15 Merieux Inst Lyophilisation stabiliser - for viruses contg potassium phosphate lactose and albumin
NL7115348A (es) * 1970-11-25 1972-05-29
US3783098A (en) * 1971-08-10 1974-01-01 Cornell Res Foundation Inc Highly potent,viable and stable cellfree virus preparations from cells infected with cell-associated viruses and method for obtaining the same
IL44143A0 (en) * 1973-02-07 1974-05-16 Wellcome Found Method of inactivating viruses and vaccines prepared thereby
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
DE2816349A1 (de) * 1978-04-14 1979-10-25 Merck & Co Inc Vaccinstabilisator
FR2424031A1 (fr) * 1978-04-24 1979-11-23 Merck & Co Inc Stabilisateur de vaccin
BE866330A (fr) * 1978-04-25 1978-10-25 Merck & Co Inc Procede de fabrication d'un agent de stabilisation de vaccin
LU79529A1 (fr) * 1978-04-26 1978-11-28 Merck & Co Inc Procede de fabrication d'un agent de stabilisation de vaccin

Also Published As

Publication number Publication date
IE802225L (en) 1981-04-29
DK159100C (da) 1991-02-11
PT71926A (en) 1980-11-01
PT71926B (en) 1982-03-31
DK159100B (da) 1990-09-03
ES496358A0 (es) 1982-02-01
EP0028563A1 (en) 1981-05-13
DE3067376D1 (en) 1984-05-10
EP0028563B1 (en) 1984-04-04
IE50276B1 (en) 1986-03-19
GR70319B (es) 1982-09-10
DK455880A (da) 1981-04-30

Similar Documents

Publication Publication Date Title
ES8202584A1 (es) Un procedimiento para la preparacion de una vacuna viral vi-va estabilizada y mejorada.
DK0500917T3 (da) Vacciner og fremgangsmåder baseret på rekombinante herpes simplex virusser.
UA42089C2 (uk) Протигрипозна вакцина на основі поверхневого антигену, спосіб її виробництва
KR970009347B1 (en) Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3
EP0841941A4 (en) Novel non-pyrogenic bacterial strains and their use
IL77694A (en) Canine parvovirus vaccines comprising viruses of the canine parvovirus strain 154 or viruses derived therefrom by additional cell culture passaging
UA40571C2 (uk) Мутант коров'ячого вірусу герпесу типу 1 (bhv-1), композиція вакцини для вакцинації тварин для захисту їх від bhv-1, композиція вакцини для вакцинації тварин для захисту їх від патогена
ATE79548T1 (de) Herpes simplex virus subunitimpfstoff.
GB1183506A (en) New vaccines for combating influenza and the preparation thereof
GB1522006A (en) Feline calicivirus vaccine and a process for the production thereof
JPS5299289A (en) Preparation of l-arginine by fermentation
CA2116355A1 (en) Infectious bovine rhinotracheitis virus mutants and vaccines
IE40221B1 (en) Influenza vaccines
MX9602256A (es) Vacuna contra la enfermedad de marek.
GB1358321A (en) Method od tissue cell culture
EP0256792A3 (en) Vaccines for fowl colibacillosis
GB1243252A (en) Stable poliomyelitis vaccines and process for their manufacture
GB1481650A (en) Chemical processes and products
SU563175A1 (ru) Разбавитель дл сухой вирусвакцины против болезней марека
IL67818A (en) Vaccines comprising ozone inactivated viruses and their production
PT69953A (en) Process for preparing a composition comprising a lyophilized herpes virus
ES468960A1 (es) Un procedimiento para la preparacion de una vacuna viral vi-va estabilizada mejorada
DE3279264D1 (en) Method of immunizing pigs against aujeszky's disease
GB8431253D0 (en) Biological preparations
UA24024C2 (uk) Вакциhа ротавірусhа іhактивоваhа для імуhізації твариh